Moderna-Merck cancer vaccine trial succeeds

A personalised mRNA cancer vaccine developed by Moderna and Merck has shown a 50% reduction in the risk of melanoma recurrence in a Phase 3 trial.

The vaccine, tailored to each patient's tumour, is designed to train the immune system to attack cancer cells.

This landmark result is expected to accelerate the development of similar vaccines for other cancers.

Moderna's stock surged on the news, reflecting the commercial potential of the therapy.